Skip to main content
Premium Trial:

Request an Annual Quote

Chromos Molecular Systems and Pfizer, Cell Signaling Technology and Chiron, NCI and GeneGo, and Qiagen and NCI

Premium

Chromos Licenses Cellular Engineering Tech to Pfizer

Chromos Molecular Systems said last week that it will non-exclusively license to Pfizer its ACE System to develop cell lines for research, development, and manufacturing of Pfizer products.

The licensing agreement expands upon an original agreement announced in December, under which Chromos is using the ACE System to engineer cell lines to express a Pfizer protein. Pfizer will continue to support this work, Chromos said.

Financial terms of the deal were not disclosed.


Cell Signaling Technology and Chiron Conduct Joint Study

Cell Signaling Technology said last week that it has reached an agreement with Chiron to perform a pilot study using CST's PhosphoScan technology to identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets.

Further terms of the agreement were not disclosed.


NCI Licenses GeneGo's Pathway Analysis Software

GeneGo has licensed its pathway analysis software to the National Cancer Institute, the St. Joseph, Mich.-based company said last week.

Under the agreement, all NCI researchers have access to the 2.5 version of GeneGo's MetaCore software through their web browsers, GeneGo said.


Qiagen and NCI to Develop siRNAs for Cancer Research

Qiagen and the National Cancer Institute will co-develop and validate a set of siRNAs for cancer genes for use by NCI researchers, Qiagen said last week.

The validated siRNA set will be made available to the general research community following the characterization project, Qiagen said.

Financial terms of the deal were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.